Currently, two BRAF-MEK inhibitor combinations, dabrafenib–trametinib and vemurafenib–cobimetinib, were FDA-approved on 9 January 2014 and 10 November 2015, respectively, for the treatment of unresectable or metastatic BRAF mutant melanoma [21,22]. This evidence concerns the gene MAP2K7 and melanoma.